Posted by Michael Wonder on 30 Sep 2017
Novo Nordisk's new fast-acting mealtime insulin Fiasp approved in the US
29 September 2017 - Novo Nordisk today announced that the US FDA has approved Fiasp (fast-acting insulin aspart), a new fast-acting mealtime insulin, for the treatment of adults with diabetes.
The FDA's decision comes after Fiasp in clinical trials demonstrated benefits for people in need of improved overall glucose control.
Fiasp is an innovative formulation of insulin aspart (NovoLog) developed with the aim of obtaining pharmacokinetic and pharmacodynamic properties that more closely match the natural physiological insulin mealtime response of a person without diabetes.
